Anti-CCR7 antibodies for the treatment of cancer

Abstract

This patent application describes the use of anti-CCR7 antibodies or antigen-binding fragments thereof as a potential treatment for cancer. Anti-CCR7 antibodies have been shown to be capable in vitro of blocking the migration of chronic lymphocytic leukaemia (CLL) cancer cells expressing the CCR7 receptor. Moreover, these antibodies are described to selectively kill CCR7 expressing CLL cells in vitro. This application claims that antibodies that recognise CCR7 could be used as therapy because they could potentially impair migration and/or block dissemination of cancer cells or target and kill tumour cells that express the CCR7 receptor.

Keywords::

• antibody
• cancer
• chemokine receptor